Angiotensin II
Also referenced as: Giapreza
An endogenous octapeptide used as a vasopressor in a defined critical-care setting.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Giapreza is FDA-approved to increase blood pressure in adults with septic or other distributive shock.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An endogenous octapeptide used as a vasopressor in a defined critical-care setting.
Giapreza is FDA-approved to increase blood pressure in adults with septic or other distributive shock.
A blood-pressure response is not evidence of cardiovascular wellness or improved longevity.
Why It's Being Studied
- Distributive shock
- Vascular signalling
Mechanism of Action
AT1-receptor activation causes vasoconstriction, increasing blood pressure.
AT1-receptor activation causes vasoconstriction, increasing blood pressure. A blood-pressure response is not evidence of cardiovascular wellness or improved longevity.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Distributive shock
- Vascular signalling
- Intravenous approved medicine
Evidence Summary
Human evidence supports blood-pressure response in distributive shock, not a proven general survival benefit.
Higher tiers carry more weight. Filled tiers have evidence for Angiotensin II; tap to read it.
- Human evidence supports blood-pressure response in distributive shock, not a proven general survival benefit.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human evidence supports blood-pressure response in distributive shock, not a proven general survival benefit.
Reported Adverse Events in Research
- Arterial and venous thrombosis and ischemic risks require critical-care monitoring.
Limitations of Current Evidence
- A blood-pressure response is not evidence of cardiovascular wellness or improved longevity.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Angiotensin II | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Angiotensin II — prescribing label